| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 19.105 | 36.710 | 23.021 | 25.535 | 50.943 | 24.095 | 28.746 | 35.221 | 29.383 | 33.375 |
| Total Income - EUR | 19.105 | 36.711 | 23.022 | 25.535 | 50.943 | 27.279 | 28.749 | 35.221 | 29.384 | 33.375 |
| Total Expenses - EUR | 18.157 | 22.729 | 31.603 | 55.995 | 78.208 | 42.138 | 41.726 | 41.042 | 45.525 | 45.624 |
| Gross Profit/Loss - EUR | 948 | 13.982 | -8.581 | -30.459 | -27.265 | -14.860 | -12.977 | -5.821 | -16.142 | -12.249 |
| Net Profit/Loss - EUR | 375 | 13.411 | -8.811 | -30.719 | -27.774 | -15.101 | -13.265 | -6.348 | -16.435 | -12.583 |
| Employees | 4 | 7 | 9 | 10 | 7 | 3 | 2 | 1 | 2 | 2 |
Check the financial reports for the company - Lipoendermoliza Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.360 | 8.504 | 17.166 | 23.119 | 22.123 | 19.249 | 15.263 | 13.132 | 9.336 | 5.838 |
| Current Assets | 4.040 | 5.069 | 4.249 | 5.974 | 7.436 | 12.519 | 10.642 | 4.439 | 2.921 | 3.463 |
| Inventories | 0 | 81 | 0 | 0 | 0 | 1.063 | 194 | 0 | 0 | 478 |
| Receivables | 1.333 | 2.162 | 2.984 | 5.623 | 6.821 | 7.064 | 6.947 | 1.858 | 1.780 | 1.670 |
| Cash | 2.707 | 2.825 | 1.266 | 351 | 615 | 4.392 | 3.501 | 2.581 | 1.140 | 1.316 |
| Shareholders Funds | -6.786 | 6.693 | -2.231 | -32.866 | -60.003 | -73.967 | -85.591 | -92.204 | -108.360 | -120.337 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 12.187 | 6.880 | 23.646 | 61.958 | 89.562 | 105.735 | 111.497 | 109.775 | 120.617 | 129.638 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "9604 - 9604" | |||||||||
| CAEN Financial Year |
9604
|
|||||||||
Comments - Lipoendermoliza Srl